A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis - PubMed
4 hours ago
- #Bone Density
- #Romosozumab
- #Osteoporosis
- Romosozumab shows strong real-world effectiveness in improving bone density, especially at the lumbar spine.
- Treatment-naïve patients benefit the most from romosozumab therapy.
- Lumbar spine improvements with romosozumab surpass those achieved with teriparatide or anti-resorptive therapies.
- Longer prior exposure to anti-resorptives is associated with reduced response to romosozumab.
- Romosozumab outperforms teriparatide and standard anti-resorptive therapies in bone mineral density (BMD) gains.
- Prior anti-resorptive use may weaken romosozumab's anabolic effects, suggesting optimal benefits for treatment-naïve patients.